Preeclampsia: definition, new in pathogenesis, guidelines, treatment and prevention

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


The review reflects current views on the diagnosis, etiology, classification, pathogenesis and methods of treatment and prevention of preeclampsia. Theories of pathogenesis are described in detail, methodical recommendations are given. Comparisons of guidelines of international societies, their goals and methods of treatment of preeclampsia are presented.

Full Text

Restricted Access

About the authors

V. A. Kaptilnyy

I.M. Sechenov First Moscow State Medical University

Author for correspondence.

Russian Federation, Moscow

D. Yu. Reyshtat

I.M. Sechenov First Moscow State Medical University


Russian Federation, Moscow


  1. Roberts J.M., Hubel C.A. The two stage model of preeclampsia: Variations on the theme. Placenta. 2009; 30 (Suppl. A): S32-S37.
  2. Roberts J.M., Taylor R.N., Musci T.J., Rodgers G.M., Hubel C.A., McLaughlin M.K. Preeclampsia: an endothelial cell disorder. Am. J. Obstet. Gynecol. 1989; 161: 1200-4.
  3. Sircar M., Thadhani R., Karumanchi S.A. Pathogenesis of pre-eclampsia. Curr. Opin. Nephrol. Hypertens. 2015; 24: 131-8.
  4. Gilbert J.S., Babcock S.A., Granger J.P. Hypertension produced by reduced uterine perfusion in pregnant rats is associated within creased soluble fms-like tyrosine kinase-1 expression. Hypertension. 2007; 50: 1142-7.
  5. Kaufmann P., Black S., Huppertz B. Endovascular trophoblast invasion: Implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol. Reprod. 2003; 69: 1-7.
  6. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 2003;111: 649-58.
  7. Venkatesha S., Toporsian M., Lam C., Hanai J., Mammoto T., Kim Y.M. et al. Soluble endogling contributes to the pathogenesis of preeclampsia. Nat. Med. 2006;12: 642-9.
  8. Rana S., Schnettler W.T., Powe C., Wenger J., Salahuddin S., Cerdeira A.S. et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens. Pregnancy. 2013; 32: 189-201.
  9. Zeisler H., Llurba E., Chantraine F., Vatish M., Staff A.C., Sennstrom M. et al. Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 2016; 374: 13-22.
  10. Rolfo A., Attini R., Nuzzo A.M., Piazzese A., Parisi S., Ferraresi M. et al. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int. 2013; 83: 177-81.
  11. Bainbridge S.A., Farley A.E., McLaughlin B.E., Graham C.H., Marks G.S., Nakatsu K. et al. Carbon monoxide decreases perfusion pressure in isolated human placenta. Placenta. 2002; 23: 563-9.
  12. McCaig D., Lyall F. Inhibitors of heme oxygenase reduce invasion of human primary cytotrophoblast cells in vitro. Placenta. 2009; 30: 536-8.
  13. Ahmed A., Rahman M., Zhang X., Acevedo C.H., Nijjar S., Rushton I., et al. Induction of placental heme oxygenase-1 is protective against TNFalpha-induced cytotoxicity and promotes vessel relaxation. Mol. Med. 2000; 6(5): 391-409.
  14. Aoki Y., Yamamoto T., Fumihisa C., Nakamura A., Asanuma A., Suzuki M. Effect on the production of soluble endoglin from human choriocarcinoma cells by preeclampsia sera. Am. J. Reprod. Immunol. 2012; 67: 413-20.
  15. Cudmore M., Ahmad S., Al-Ani B., Fujisawa T., Coxall H., Chudasama K. et al. Negative regulation of soluble Flt-1 and soluble endoglin release byheme oxygenase-1. Circulation. 2007; 115: 1789-97.
  16. Baum M., Schiff E., Kreiser D., Dennery P.A., Stevenson D.K., Rosenthal T., Seidman D.S. End-tidal carbon monoxide measurements in women with pregnancy-induced hypertension and preeclampsia. Am. J. Obstet. Gynecol. 2000; 183 (4): 900-3.
  17. Zhao W., Zhang J., Lu Y., Wang R. The vasorelaxant effect of H(2)Sas a novel endogenous gaseous K(ATP) channel opener. EMBO J. 2001; 20: 6008-16.
  18. Holwerda K.M., Burke S.D., Faas M.M., Zsengeller Z., Stillman I.E., Kang P.M. et al. Hydrogen sulfide attenuates sFlt1-induced hyperten-sion and renal damage by upregulating vascular endothelial growth factor. J. Am. Soc. Nephrol. 2014; 25: 717-25.
  19. Wang K., Ahmad S., Cai M., Rennie J., Fujisawa T., Crispi F., et al. Dysregulation of hy-drogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalitiesin preeclampsia. Circulation. 2013; 127: 2514-22.
  20. Snijder P.M., Frenay A.R., Koning A.M., Bachtler M., Pasch A., Kwakernaak A.J., Sodium thiosulfate attenuates angiotensin II-induced hypertension, proteinuria and renaldamage. Nitric Oxide. 2014; 42: 87-98.
  21. Selk N., Rodby R.A. Unexpectedly severe metabolic acidosis associated with sodium thiosulfate therapy in a patient with calcific uremic arteriolopathy. Semin. Dial. 2011; 24: 85-8.
  22. Quillon A., Fromy B., Debret R. Endothelium microenvironment sensing leading to nitric oxide mediated vasodilation: A review of nervous and biomechanical signals. Nitric Oxide. 2015; 45: 20-6.
  23. Lowe D.T. Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide. 2000; 4: 441-58.
  24. Bernardi F., Constantino L., Machado R., Petronilho F., Dal-Pizzol F. Plasma nitric oxide, endothelin-1, arginase and superoxide dismutase in preeclamptic women. J. Obstet. Gynaecol. Res. 2008; 34: 957-63.
  25. Kulandavelu S., Whiteley K.J., Qu D., Mu J., Bainbridge S.A., Adamson S.L. Endothelial nitric oxide synthase deficiency reduces uterine blood flow, spiral artery elongation, and placental oxygenation in pregnant mice. Hypertension. 2012; 60: 231-8.
  26. Myatt L., Cui X. Oxidative stress in the placenta. Histochem. Cell Biol. 2004; 122: 369-82.
  27. Raijmakers M.T., Peters W.H., Steegers E.A., Poston L. NAD(P)H oxidase associated superoxide production in human placenta from normotensive and pre-eclamptic women. Placenta. 2004; 25(Suppl A): S85-9.
  28. Poston L., Briley A.L., Seed P.T., Kelly F.J., Shennan A.H. Vitamins in Pre-eclampsia (VIP) Trial Consortium: Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): Randomised placebo-controlled trial. Lancet. 2006; 367: 1145-54.
  29. Wallukat G., Homuth V., Fischer T., Lindschau C., Horstkamp B., Jupner A. et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J. Clin. Invest. 1999; 103: 945-52.
  30. Dechend R., Viedt C., Muller D.N., Ugele B., Brandes R.P., Wallukat G., et al. AT1 receptor agonistic anti-bodies from preeclamptic patients stimulate NADPH oxidase. Circulation. 2003; 107: 1632-9.
  31. Buhimschi I.A., Nayeri U.A., Zhao G., Shook L.L., Pensalfini A., Funai E.F., et al. Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. Sci. Transl. Med. 2014; 6: 245ra92.
  32. Ness R.B., Roberts J.M. Heterogeneous causes constituting the single syndrome of preeclampsia: A hypothesis and its implications. Am. J. Obstet. Gynecol. 1996; 175: 1365-70.
  33. Von Dadelszen P., Magee L.A., Roberts J.M. Subclassification of preeclampsia. Hypertens. Pregnancy. 2003; 22: 143-8.
  34. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 2004; 350: 672-83.
  35. Papageorghiou A.T., Campbell S. First trimester screening for preeclampsia. Curr. Opin. Obstet. Gynecol. 2006; 18: 594-600.
  36. Aardema M.W., Oosterhof H., Timmer A., van Rooy I., Aarnoudse J.G. Uterine artery Doppler flow and uteroplacental vascular pathology in normal pregnancies and pregnancies complicated by preeclampsia and small for gestational age fetuses. Placenta. 2001; 22: 405-11.
  37. Moldenhauer J.S., Stanek J., Warshak C., Khoury J., Sibai B. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am. J. Obstet. Gynecol. 2003; 189: 1173-7.
  38. Murphy D.J., Stirrat G.M. Mortality and morbidity associated with early-onset preeclampsia. Hypertens. Pregnancy. 2000; 19: 221-31.
  39. Amaral L.M., Cunningham M.W. Jr., Cornelius D.C., LaMarca B. Preeclampsia: Long-term consequences for vascular health. Vasc. Health Risk Manag. 2015; 11: 403-15.
  40. Sibai B., Dekker G., Kupferminc M. Preeclampsia. Lancet. 2005; 365: 785-99.
  41. Ahmed R., Dunford J., Mehran R., Robson S., Kunadian V. Pre-eclampsia and future cardiovascular risk among women: a review. J. Am. Coll. Cardiol. 2014; 63: 1815-22.
  42. Bellamy L., Casas J.P., Hingorani A.D., Williams D.J. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007; 335: 974.
  43. Lin Y.S., Tang C.H., Yang C.Y., Wu L.S., Hung S.T., Hwa H.L., Chu P.H. Effect of pre-eclampsia-eclampsia on major cardiovascular events among peripartum women in Taiwan. Am. J. Cardiol. 2011; 107: 325-30.
  44. Vikse B.E., Irgens L.M., Leivestad T., Skjaerven R., Iversen B.M. Preeclampsia and the risk of end-stage renal disease. N. Engl. J. Med. 2008; 359: 800-9.
  45. Al-Nasiry S., Ghossein-Doha C., Polman S.E., Lemmens S., Scholten R.R., Heidema W.M., et al. Metabolic syndrome after pregnancies complicated by preeclampsia or small-for-gestational-age: a retrospective cohort. BJOG. 2015; 122: 1818-23.
  46. Lisonkova S., Sabr Y., Mayer C., Young C., Skoll A., Joseph K.S. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet. Gynecol. 2014; 124: 771-81.
  47. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy: Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am. J. Obstet. Gynecol. 2000; 183: S1-22.
  48. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy: Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet. Gynecol. 2013; 122: 1122-31.
  49. Magee L.A., Pels A., Helewa M., Rey E., von Dadelszen P. Canadian Hypertensive Disorders of Pregnancy (HDP) Working Group: Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014; 4: 105-45.
  50. Lowe S.A., Bowyer L., Lust K., McMahon L.P., Morton M.R., North R.A. et al. Society of Obstetric Medicine of Australia and New Zealand: the SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy 2014. Aust. N. Z. J. Obstet. Gynaecol. 2015; 55: 11-6.
  51. Tranquilli A.L., Dekker G., Magee L., Roberts J., Sibai B.M., Steyn W. et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a re-vised statement from the ISSHP. Pregnancy Hypertens. 2014; 4: 97-104.
  52. Magee L.A., von Dadelszen P., Rey E., Ross S., Asztalos E., Murphy K.E. et al. Less-tight versus tight control of hypertension in pregnancy. N. Engl. J. Med. 2015; 372: 407-17.
  53. Abalos E., Duley L., Steyn D.W., Henderson-Smart D.J. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst. Rev. 2007; (1): CD002252.
  54. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., Dudley J.A., Dyer S., Gideon P.S. et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N. Engl. J. Med. 2006; 354: 2443-51.
  55. Hofmeyr G.J., Lawrie T.A., Atallah A.N., Duley L., Torloni M.R. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst. Rev. 2018; 10: CD001059.
  56. Rumbold A.R., Crowther C.A., Haslam R.R., Dekker G.A., Robinson J.S. ACTS Study Group: vitamins C and E and the risks of pre-eclampsia and perinatal complications. N. Engl. J. Med. 2006; 354:1796-806.
  57. Bujold E., Roberge S., Lacasse Y., Bureau M., Audibert F., Marcoux S. et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet. Gynecol. 2010; 116: 402-14.
  58. Henderson J.T., Whitlock E.P., O’Connor E., Senger C.A., Thompson J.H., Rowland M.G. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2014; 160: 695-703.
  59. Dodd J.M., McLeod A., Windrim R.C., Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst. Rev. 2013; 7: CD006780.
  60. Phipps E., Prasanna D., Brima W., Jim B. Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clin. J. Am. Soc. Nephrol. 2016; 11(6):1102-13.

Supplementary files

Supplementary Files Action
Fig. 1. The main pathogenetic links in preeclampsia.

Download (263KB) Indexing metadata
Fig. 2. Therapeutic tactics depending on the gestational age.

Download (294KB) Indexing metadata



Abstract - 188

PDF (Russian) - 17


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2020 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies